Shenzhen Chipscreen Faces Flat Performance, Investors Question Growth Potential
Shenzhen Chipscreen Biosci sees a flat day amid a 14% decline, raising doubts over its life‑science tech and growth plans. Investors weigh low valuation, weak volume and a steep technical downtrend before deciding.
4 minutes to read